Director Appointment

Tristel plc

("Tristel" or the "Company")

Director Appointment

Tristel plc (AIM: TSTL), the manufacturer of infection prevention and contamination control products utilising proprietary chlorine dioxide chemistry, announces the appointment of Dr. Bruno Holthof to its Board as a non-executive director.

Dr. Bruno Holthof is the Chief Executive Officer of Oxford University Hospitals ("OUH"). Before OUH, he was CEO of the Antwerp Hospital Network from January 2004 until September 2015. Bruno Holthof is also Chair of the Board of Armonea, a European private care home provider.

Before becoming a CEO, he was a partner at McKinsey & Company. During this period, he served a wide range of healthcare clients in Europe and the United States and gained significant expertise in the areas of strategy, organisation and operations. He holds an MBA from the Harvard Business School and an MD/PhD from the University of Leuven.

Commenting on the appointment, Paul Swinney, CEO of Tristel, said: "We are delighted to welcome Bruno to our Board. Bruno has more than 10 years of board level experience on publicly listed companies. He also brings to the Board an in-depth knowledge and operational experience of healthcare systems in different markets. We very much look forward to working together."

For further information please contact:

Regulatory disclosure - The following information is disclosed in accordance with Rule 17 and paragraph (g) of Schedule 2 of the AIM Rules for Companies.

Bruno Luc Myriam Holthof, 57, holds nil ordinary shares in the Company and nil options. Dr. Holthof current and previous directorships are as follows:

Current Directorships/Partnerships:

Project Tower Member 2 Limited

Praksis UK Ltd

Shelford Health Roundtable

Oxford University Hospital NHS Foundation Trust

Armonea Group NV

Directorship held in last 5 years:

Barco NV

BPost NV/SA

Save for the disclosures above, there are no further disclosures to be made in accordance with Rule 17 and Schedule 2(g) of the AIM Rules.